Pfizer To Expand In China To Cushion Lipitor Patent Expiration
This article was originally published in PharmAsia News
Executive Summary
Pfizer plans to expand its operations in China as part of a cost-cutting response to the looming lapse of the patent on its Lipitor (atorvastatin) anti-cholesterol statin. CFO Frank D'Amelio said Pfizer plans to outsource more of its manufacturing operations in preparation for generic competition to its best-selling drug. The patent expires in November 2011. D'Amelio said Pfizer also plans to expand the number of drugs it pursues in other areas. (Click here for more